Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib

22 Sept 2021

Abstract excerpt

Abstract Purpose: The European Organization for Research and Treatment of Cancer (EORTC) clinical phase II trial 90101 “CREATE” showed high antitumor activity of crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK)/ROS1, in patients with advanced inflammatory myofibroblastic tumor (IMFT). However, recent findings suggested that other molecular targets in addition to ALK/ROS1 might also contribute to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to IgG4-Related and Inflammatory Diseases
Share to Neuroendocrine Tumor Research Advances
Share to Otitis Media and Relapsing Polychondritis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34551905
DOI: 10.1158/1078-0432.ccr-21-1165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to CrizotinibPMID 34551905Read ↗

Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsSemantic proximity Read ↗

Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic CancerSemantic proximity Read ↗

Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET RearrangementSemantic proximity Read ↗

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.Semantic proximity Read ↗

ALK-Negative Lung Inflammatory Myofibroblastic Tumor in a Young Adult: a Case Report and Literature Review of Molecular AlterationsSemantic proximity Read ↗

ALK‑G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case reportSemantic proximity Read ↗

Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.Semantic proximity Read ↗

ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic TumorsSemantic proximity Read ↗

An Inflammatory Myofibroblastic Tumor With a Novel ALKV1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumorsSemantic proximity Read ↗

A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature reviewSemantic proximity Read ↗

Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene RearrangementsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.